# US 9,517,993 B2 · Antagonists of the toll-like receptor 1/2 complex

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,517,993 B2
- Document ID: US9517993B2
- Status: Granted
- Kind: B2
- Application number: 14/417,676
- Filed: 2013-07-29
- Published: 2015-09-10
- Granted: 2016-12-13
- Earliest claimed: 2012-07-29
- Assignees: The Regents of the University of Colorado, a body corporate
- Applicants: THE REGENTS OF THE UNIVERSITY OF COLORADO, a body corporate
- Inventors: Hang Yin; Kui Cheng
- Web page: https://patentgrep.com/patent/US9517993B2

## CPC

- C07C 49/747: containing six-membered aromatic rings
- C07C 49/755: a keto group being part of a condensed ring system with two or three rings, at least one ring being a six-membered aromatic ring
- C07C 62/38: containing keto groups
- C07C 69/21: of hydroxy compounds with more than three hydroxy groups (esters of sugars C07H)
- C07C 69/757: having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, [IMAGE cpc-sch-C07C-0958.gif] groups,[IMAGE cpc-sch-C07C-0959.gif] groups, or[IMAGE cpc-sch-C07C-0960.gif] in the acid moiety
- C07C 235/82: with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07D 307/93: condensed with a ring other than six-membered
- C07C 2602/12: the other ring being at least seven-membered
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Provided are compounds, compositions and methods for treating Toll-like receptor 1/2 complex (TLRI/2) related inflammatory disorders. Small molecules, based on the benzotropolone scaffold, capable of influencing downstream signaling are disclosed as well as methods of making and modifying these molecules. Also provided are methods for treating a subject for a clinical condition associated with Toll-like receptor complex 1/2 activation, comprising administering to the subject an effective amount of a benzotropolone compound.

## Claims

### Claim 1

A compound having the chemical structure:
or a pharmaceutically acceptable salt thereof.

### Claim 2

A compound having the chemical structure:
or a pharmaceutically acceptable salt thereof.

### Claim 3

A compound having the chemical structure:
or a pharmaceutically acceptable salt thereof.

### Claim 4

A compound having the chemical structure:
or a pharmaceutically acceptable salt thereof.

### Claim 5

A compound having the chemical structure:
or a pharmaceutically acceptable salt thereof.

### Claim 6

A compound having the chemical structure:
or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1, 2, 3, 4, 5)

A pharmaceutical composition comprising a compound of claims 1, 2, 3, 4, 5, or 6, or a salt thereof, and a pharmaceutically acceptable excipient.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6)

A method for treating a clinical condition associated with signaling mediated by TLR1/2 comprising administering to a subject in need of such a treatment a therapeutically effective amount of a compound of any one of claims 1-6, wherein the clinical condition is psoriasis or acne vulgaris.